KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Other Working Capital Changes (2016 - 2025)

Teva Pharmaceutical Industries' Other Working Capital Changes history spans 10 years, with the latest figure at -$2.9 billion for Q4 2025.

  • For the quarter ending Q4 2025, Other Working Capital Changes fell 1293.88% year-over-year to -$2.9 billion, compared with a TTM value of -$2.8 billion through Dec 2025, down 471.49%, and an annual FY2025 reading of -$1.3 billion, down 405.75% over the prior year.
  • Other Working Capital Changes for Q4 2025 was -$2.9 billion at Teva Pharmaceutical Industries, down from $27.0 million in the prior quarter.
  • The five-year high for Other Working Capital Changes was $1.1 billion in Q1 2021, with the low at -$2.9 billion in Q4 2025.
  • Average Other Working Capital Changes over 5 years is -$169.5 million, with a median of $6.5 million recorded in 2021.
  • Year-over-year, Other Working Capital Changes skyrocketed 53700.0% in 2021 and then tumbled 1433.33% in 2022.
  • Tracing TEVA's Other Working Capital Changes over 5 years: stood at -$2.3 billion in 2021, then surged by 140.41% to $916.0 million in 2022, then plummeted by 95.31% to $43.0 million in 2023, then skyrocketed by 469.77% to $245.0 million in 2024, then plummeted by 1293.88% to -$2.9 billion in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Other Working Capital Changes are -$2.9 billion (Q4 2025), $27.0 million (Q3 2025), and $105.0 million (Q2 2025).